Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institute of Allergy and Infectious Diseases (NIAID) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) American Diabetes Association Juvenile Diabetes Research Foundation |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00279305 |
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Without these beta cells, the body cannot maintain proper blood glucose levels in response to daily activities such as eating or exercise. With fewer insulin producing cells blood glucose increases, causing hunger, thirst, and unexplained weight loss. By the time these symptoms develop, 80-90% of a person's beta cells have already been destroyed. However, this also means that between 10-20% of these cells remain that continue to produce insulin.
Scientists have learned that two types of immune cells, B cells and T cells, are involved in causing type 1 diabetes. T cells are responsible for attacking and destroying the beta cells that make insulin. Although they don't attack insulin producing cells, B cells may be what trigger the T cells to attack.
This study will investigate the use of rituximab to see if it can help lower the number of immune B cells thereby preventing the destruction of any remaining insulin producing beta cells that remain at diagnosis. Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of a condition called B-lymphocyte lymphoma. Its effects on the immune system are well understood through its use in organ transplantation. Research has shown that rituximab might be helpful in treating other conditions caused by T cells and B cells, including type 1 diabetes. The goal of this study is to find out if rituximab can preserve residual insulin secretion and prevent further beta cell destruction in type 1 diabetes.
Condition | Intervention | Phase |
---|---|---|
Type 1 Diabetes Mellitus |
Drug: Anti-CD20 (rituximab) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Enrollment: | 87 |
Study Completion Date: | December 2006 |
The study is a randomized, two-arm, trial in which 2/3 of participants will receive the study drug, while the remaining 1/3 will receive a placebo (a pretend medicine that does nothing). The group you are assigned to is decided by chance (as by the toss of a coin or drawing straws). Neither you nor your doctor will be able to choose which group you are in. Also, neither you nor the researchers will know which group you are in. Participants will take rituximab, or the placebo, once a week during the first 4 weeks in the study. It will be given as an intravenous infusion at a clinical center.
Participants will need to return to the clinical center for a visit about every 3 months for two years; those participants that continue to secrete insulin will have further follow-up for an additional two years.
Ages Eligible for Study: | 8 Years to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Childrens Hospital of Los Angeles | |
Los Angeles, California, United States, 90027 | |
Stanford University | |
Stanford, California, United States, 94305 | |
University of California-San Francisco | |
San Francisco, California, United States, 94143 | |
United States, Colorado | |
Barbara Davis Center for Childhood Diabetes | |
Aurora, Colorado, United States, 80010 | |
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610-0296 | |
University of Miami | |
Miami, Florida, United States, 33136 | |
United States, Indiana | |
Indiana University-Riley Hospital for Children | |
Indianapolis, Indiana, United States, 46202 | |
United States, Massachusetts | |
Joslin | |
Boston, Massachusetts, United States, 02215 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Columbia University | |
New York, New York, United States, 10032 | |
Columbia University | |
New York, New York, United States, 10032 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
University of Texas | |
Dallas, Texas, United States, 75235-8858 | |
United States, Washington | |
Benaroya Research Institute | |
Seattle, Washington, United States, 98101 | |
Australia | |
Walter and Eliza Hall Institute of Medical Research | |
Victoria, Australia | |
Canada, Ontario | |
The Hospital for Sick Children | |
Toronto, Ontario, Canada, M5G 1X8 | |
Italy | |
San Raffaele Hospital | |
Milan, Italy |
Principal Investigator: | Mark Pescovitz, MD | Type 1 Diabetes TrialNet |
Study ID Numbers: | Ritux |
Study First Received: | January 17, 2006 |
Last Updated: | January 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00279305 |
Health Authority: | United States: Food and Drug Administration |
Newly diagnosed type 1 diabetes New Onset type 1 diabetes Preservation of insulin secretion Type 1 diabetes |
Juvenile Onset Diabetes Insulin Dependent Diabetes T1D |
Autoimmune Diseases Metabolic Diseases Diabetes Mellitus, Type 1 Rituximab Disease Progression Diabetes Mellitus |
Endocrine System Diseases Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Insulin |
Immunologic Factors Immune System Diseases Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |